The biotechnology sector is experiencing a surge in innovation as companies develop advanced therapies to address complex diseases. This wave of progress is particularly evident in the development of novel treatments for autoimmune disorders, where cutting-edge cell therapies hold promise to transform patient care.

Wed, Aug. 20, 2025

Topline data for registrational Phase 2 trial of KYV-101 in stiff person syndrome (SPS) and BLA submission anticipated in 1H 2026

Tue, Aug. 12, 2025

Webcast to be held August 28, 2025, 11:00am ET EMERYVILLE, Calif. , July 29, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that the Company will host a webcast event with Key Opinion Leaders (KOLs) to discuss its neuroimmunology franchise.

Tue, Jul. 29, 2025

NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Kyverna Therapeutics, Inc. (NASDAQ: KYTX) on behalf of long-term stockholders following a class action complaint that was filed against Kyverna on December 9, 2024 with a Class Period pursuant and/or traceable to the Company's offering documents issued in connection with its initial public offering (“IPO”) conducted on February 8, 2024. Our investigation concerns whether the board of directors of Kyverna have breached their fiduciary duties to the company.

Wed, Jul. 02, 2025

Squarepoint Ops LLC acquired a new stake in Kyverna Therapeutics, Inc. (NASDAQ:KYTX – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 11,488 shares of the company’s stock, valued at approximately $43,000. A number of other institutional investors have also made changes to their positions in KYTX. Corton Capital Inc. bought a new position in Kyverna Therapeutics in the 4th quarter worth approximately $45,000. Corebridge Financial Inc. increased its position in Kyverna Therapeutics by 42.3% in the 4th quarter. Corebridge Financial Inc. now owns 12,811 shares of the company’s stock worth $48,000 after buying an additional 3,810 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Kyverna Therapeutics by 53.7% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,288 shares of the company’s stock worth $53,000 after buying an additional 4,990 shares during the period. Bank of America Corp DE increased its position in Kyverna Therapeutics by 41.6% in the 4th quarter. Bank of America Corp DE now owns 21,788 shares of the company’s stock worth $81,000 after buying an additional 6,400 shares during the period. Finally, Rhumbline Advisers increased its position in Kyverna Therapeutics by 31.1% in the 4th quarter. Rhumbline Advisers now owns 25,920 shares of the company’s stock worth $97,000 after buying an additional 6,153 shares during the period. 18.08% of the stock is owned by institutional investors. Kyverna Therapeutics Price Performance Shares of Kyverna Therapeutics stock opened at $3.60 on Wednesday. The business has a fifty day simple moving average of $2.24 and a two-hundred day simple moving average of $3.01. Kyverna Therapeutics, Inc. has a 1 year low of $1.78 and a 1 year high of $16.64. The company has a market capitalization of $155.59 million, a price-to-earnings ratio of -1.07 and a beta of 2.52. Kyverna Therapeutics (NASDAQ:KYTX – Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported ($1.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.21) by $0.18. As a group, equities analysts anticipate that Kyverna Therapeutics, Inc. will post -3.29 earnings per share for the current fiscal year. Analyst Upgrades and Downgrades KYTX has been the topic of a number of research reports. Morgan Stanley lowered their price objective on Kyverna Therapeutics from $40.00 to $20.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 1st. HC Wainwright upgraded Kyverna Therapeutics from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $4.00 to $5.00 in a research report on Tuesday, May 27th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $18.50. View Our Latest Stock Analysis on Kyverna Therapeutics Kyverna Therapeutics Profile (Free Report) Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.

Wed, Jun. 11, 2025